DR. MARTIN BLASER, MD
Osteopathic Medicine at 1 Ave, New York, NY

7919250, Apr 5, 2011

Jul 31, 2008

12/183806

Martin J. Blaser - New York NY, US
Zhan Gao - Elmhurst NY, US

New York University - New York NY

A61K 39/02, C07H 21/00

435 6, 435 36, 536 237

The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods will be useful for detecting, diagnosing, and monitoring individuals who have or are at risk of certain skin conditions.

5459041, Oct 17, 1995

Feb 18, 1988

7/158003

Martin J. Blaser - New York NY
Guillermo I. Perez-Perez - Denver CO

Enteric Research Laboratories, Inc. - Denver CO

G01N 3353

435 721

Antigenic compositions are disclosed for use in diagnostic kits and the like for detecting the presence of antibodies specific for Campylobacter pylori, bacteria often associated with the occurrence of Type B gastritis and peptic ulcer disease. Samples of bodily fluids, for instance, may be contacted with immobilized antigen which is then washed and tested for the occurrence of significant levels of antigen/antibody complex. Levels exceeding a predetermined positive threshold are indicative of antibodies to Campylobacter pylori in the sample tested. Kits employing the antigenic compositions of the invention preferably include means for detecting the antigen/antibody complex such as materials and reagents for conducting an enzyme-linked immunosorbent assay, Western blot technique, liposome-based assay or other known detection tests.

2010007, Mar 25, 2010

Sep 25, 2009

12/566965

Martin J. Blaser - New York NY, US
Ilseung Cho - New York NY, US

NEW YORK UNIVERSITY - New York NY

A61K 35/74, A61P 31/00, A61P 11/06, A61P 7/12, A61P 3/00

424 934

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant (MRSA), , vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

2011028, Nov 17, 2011

May 4, 2011

13/100977

Martin J. Blaser - New York NY, US

NEW YORK UNIVERSITY - NY NY

A61K 35/74, A61P 3/00, A61P 5/48, A61P 5/50, A61P 21/00, A61P 3/10, A61P 1/16, A61P 3/06, A61P 19/00, A61P 19/10, A61P 3/04, A61P 3/08

424 934

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

2012005, Mar 8, 2012

Aug 19, 2011

13/214034

Martin J. Blaser - New York NY, US
Laura Nondorf - Brooklyn NY, US
Ilseung Cho - New York NY, US
Bart Waters - Midland MI, US

DOW GLOBAL TECHNOLOGIES LLC - Midland MI
NEW YORK UNIVERSITY - New York NY

A61K 35/74, A61P 3/04, A61P 9/10, A61P 3/06, A61P 3/00, C12Q 1/68, A61P 3/08

424 9341, 435 612, 424 934, 424 9345

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota.

2012015, Jun 21, 2012

Apr 21, 2011

13/091999

Marcus B. Jones - Rockville MD, US
Martin J. Blaser - New York NY, US
Thomas Wood - Tolland CT, US
Dacheng Ren - Ithaca NY, US

UNIVERSITY OF CONNECTICUT - FARMINGTON CT
NEW YORK UNIVERSITY - NEW YORK NY

A61K 31/365, A61P 31/04

514473

The present invention pertains to the discovery that possesses a luxS gene that encodes a functional LuxS polypeptide, and that synthesizes a functional AI-2 quorum-sensing molecule. The invention provides mutant bacteria lacking the function of the luxS gene, which do not produce a functional AI-2 molecule and have growth defects compared to wild-type . The invention also concerns methods for inhibiting the growth of , or for preventing or treating infection, by inhibiting the activity of the LuxS polypeptide, or by exposure of the to furanone. In particular, the invention concerns the use of furanone, a compound that inhibits AI-2-mediated quorum-sensing, to inhibit the growth of , to inhibit toxin production, particularly that of protective antigen, and to prevent or treat infection. The invention also provides methods to prevent infection, or enhance an immune response to infection, by administering a vaccine comprising a cell in which the luxS gene is mutated.

2005004, Feb 24, 2005

Apr 12, 2004

10/823396

Marcus Jones - New York NY, US
Martin Blaser - New York NY, US
Thomas Wood - Tolland CT, US
Dacheng Ren - Ithaca NY, US

C07K014/32, C12Q001/68, C07H021/04, C12N009/10, C12N015/74

435006000, 435069300, 435252310, 435320100, 530350000, 536023700

The present invention pertains to the discovery that possesses a luxS gene that encodes a functional LuxS polypeptide, and that synthesizes a functional AI-2 quorum-sensing molecule. The invention provides mutant bacteria lacking the function of the luxS gene, which do not produce a functional AI-2 molecule and have growth defects compared to wild-type . The invention also concerns methods for inhibiting the growth of , or for preventing or treating infection, by inhibiting the activity of the LuxS polypeptide, or by exposure of the to furanone. In particular, the invention concerns the use of furanone, a compound that inhibits AI-2-mediated quorum-sensing, to inhibit the growth of , to inhibit toxin production, particularly that of protective antigen, and to prevent or treat infection. The invention also provides methods to prevent infection, or enhance an immune response to infection, by administering a vaccine comprising a cell in which the luxS gene is mutated.

2006004, Feb 23, 2006

Oct 15, 2004

10/966321

David Rosmarin - New York NY, US
Zhiheng Pei - New York NY, US
Martin Blaser - New York NY, US
Sanjay Tyagi - Newark NJ, US

C12Q 1/68, C07H 21/04

435006000, 536024100

A nucleic acid probe for identifying a target nucleic acid sequence including a linker structure including a 5′ end and a 3′ end; 5′ marker mechanism for producing an identifying signal to the target nucleic acid sequence, wherein the 5′ marker mechanism is conjugated to the 5′ end of the linker structure; and 3′ marker mechanism for producing an identifying signal to a target nucleic acid sequence, wherein the 3′ marker mechanism is conjugated to the 3′ end of the linker structure and wherein identification of the target nucleic acid sequence occurs when the 5′ marker mechanism and 3′ marker mechanism are in close physical proximity to each other. A nucleic acid probe for identifying a target nucleic acid including a marker pair mechanism for producing an identification signal to identify a target nucleic acid sequence; and linker mechanism for linking the marker pair mechanism together. A biosensor including a fluorophore quencher pair; and a linker sequence for linking the fluorophore quencher pair. A probe for use in a polymerase chain reaction (PCR).